This post was originally published on this site Combining Opdivo (nivolumab) with Adcetris (brentuximab vedotin) could be a promising option for people with advanced primary mediastinal B-cell lymphoma (PMBL), an aggressive and hard-to-treat disease, results from the CheckMate-436 trial show. About 70% of the patients responded to this combination, and the lymphoma completely disappeared in…
Conditions
Conditions
Landmarks Lit in Blue in Every US State to Launch Prostate Cancer Awareness Month
This post was originally published on this site For the first time, landmarks in all 50 U.S. states were illuminated in blue on Sept. 3 to launch Prostate Cancer Awareness Month. The Prostate Cancer Foundation‘s “Light It Blue” effort is aimed at heightening disease awareness, supporting patients, and encouraging action. More than 174,000 men will…
ADvance II Study Testing Deep Brain Stimulation in Mild Alzheimer’s Started, Enrollment Ongoing
This post was originally published on this site The first patient enrolled in the ADvance II Study has been implanted with a deep brain stimulation (DBS) device to start treatment for mild Alzheimer’s disease. The study will evaluate the safety and effectiveness of stimulating the fornix (DBS-f) — a major inflow and output pathway in…
FDA to Review Nerlynx Combo as Third-line Treatment for HER2-positive Metastatic Breast Cancer
This post was originally published on this site The U.S. Food and Drug Administration (FDA) has agreed to review Puma Biotechnology’s application seeking approval of Nerlynx (neratinib), in combination with capecitabine, to treat HER2-positive breast cancer patients with metastatic disease, the company has announced. The supplemental New Drug Application (sNDA) is for women who have failed two or…
Nanotechnology May Help Get Immunotherapy Into the Brain, Mouse Study Says
This post was originally published on this site Immunotherapies have shown little efficacy in brain cancers due to their inability to cross the blood-brain barrier. Now, however, researchers have developed a new nanotechnology approach that allowed immune checkpoint inhibitors to enter the brains of mice with glioblastoma. The approach increased the amount of immune cells…
Real Awareness Means Understanding What Cancer Patients Experience
This post was originally published on this site We’re right in the middle of Lymphoma Awareness Month. I’ve always had kind of a funny relationship with it. It seems silly to remind me to be aware of something that is such a part of who I am. And as a follicular lymphoma advocate who reads…
Partnership Aims to Identify DLBCL Patients Likely to Benefit from ADCT-402
This post was originally published on this site ADC Therapeutics announced it partnered with Freenome to identify biomarkers that can help to predict which diffuse large B-cell lymphoma (DLBCL) patients are most likely to respond to ADCT-402 (loncastuximab tesirine), its investigational antibody-drug conjugate now in a Phase 2 trial. Freenome has developed a platform that detects…
Researchers Identify Promising Target for CAR T-cell Therapy in Myeloma
This post was originally published on this site Designing CAR T-cells to specifically target GPRC5D — a protein appreciably present on the surface of myeloma cells — may be a safe and effective therapy against multiple myeloma, a preclinical study shows. The study, “GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed…
TCR2 Therapeutics, National Cancer Institute Team Up to Develop TC-210 Immunotherapy
This post was originally published on this site TCR2 Therapeutics has partnered with Raffit Hassan, MD, at the National Cancer Institute to test TC-210, a mesothelin-specific immunotherapy, in an ongoing Phase 1/2 clinical trial for people with advanced cancers that produce the mesothelin protein. Mesothelin is a protein highly abundant in several solid tumors, including…
Taking a Look at the Cognitive Assessment Disconnect
This post was originally published on this site In the time that it takes to read the first few paragraphs of this column, someone in the United States will develop Alzheimer’s disease. One person in the U.S. develops the illness every 65 seconds, according to a 2019 report. The Alzheimer’s Association indicates that just over…
PTI-125 Reduces Neurodegeneration After 28 Days of Treatment, Data Show
This post was originally published on this site PTI-125, Cassava Sciences’ lead therapeutic candidate for the treatment of Alzheimer’s disease, significantly reduced the levels of disease biomarkers, brain inflammation, and neurodegeneration after 28 days of treatment, top-line data from a Phase 2 trial show. “Based on these encouraging biomarker results, this new treatment could be…
TNBC Patient Given Investigative Antibody, Leronlimab, Under Emergency Exception
This post was originally published on this site A metastatic triple-negative breast cancer (TNBC) patient is being treated with CytoDyn’s investigational leronlimab (PRO 140) under an emergency investigational new drug (IND) application granted by the U.S. Food and Drug Administration, An emergency IND can be used by physicians to request permission to give an investigational…